All In Biotech

NDA 021630 · Pf Prism Cv

Vfend

Voriconazole · Oral · Azole Antifungal

Last checked: Nov 20, 2026Latest source record: Feb 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Dec 19, 2003

Approved uses

3

Original approval plus efficacy supplements

Registered trials

153

39 Phase 3, 14 recruiting

FAERS reports

30,722

28,342 serious, 8,951 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 2, 2026.

Voriconazole is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: • Invasive aspergillosis ( 1.1 ) • Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) • Esophageal candidiasis ( 1.3 ) • Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) 1.1 Invasive Aspergillosis Voriconazole is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus . There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus [see Clinical Studies (14.1 , 14.5 ) and Microbiology (12.4) ] . 1.2 Candidemia in Non-neutropenic Patients and Other Deep Tissue Candida Infections Voriconazole is indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds [see Clinical Studies (14.2 , 14.5 ) and Microbiology (12.4) ] . 1.3 Esophageal Candidiasis Voriconazole is indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (EC) [see Clinical Studies (14.3 , 14.5 ) and Microbiology (12.4) ] . 1.4 Scedosporiosis and Fusariosis Voriconazole is indicated for the treatment of serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii ) and Fusarium spp. including Fusarium solani , in adults and pediatric patients (2...

Mechanism: Voriconazole is an antifungal drug [see Microbiology (12.4) ] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • VFEND · VORICONAZOLE 200MG/5ML · FOR SUSPENSION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Voriconazole" as an intervention, any sponsor and status, largest first.

All 153 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,336
  • off label use2,510
  • drug interaction2,408
  • death1,481
  • pyrexia1,455
  • pneumonia1,359
  • condition aggravated1,157
  • bronchopulmonary aspergillosis1,066
  • aspergillus infection943
  • febrile neutropenia924
  • respiratory failure865
  • nausea796

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004315
2005322
2006418
2007446
2008429
2009618
2010855
2011876
20121,097
20131,062
20141,063
20151,201
20161,422
20171,997
20182,244
20192,497
20202,370
20212,184
20222,258
20231,992
20241,898
20251,869
20261,288

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vfend (Voriconazole)

2024 spending

$8K

Beneficiaries

12

19 claims

Per beneficiary

$635

$4.41 per unit

View as table
YearSpending
2020$42,158
2021$13,420
2022$8,554
2023$10,102
2024$7,623

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 407 on PubMed

Sponsor: Pf Prism Cv

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.